Should I Buy HURA? HURA 2026 Analysis

Should You Buy TuHURA Biosciences Inc (HURA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.630

1 Day change

42.95%

52 Week Range

4.770

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: price is in a strong downtrend (SMA_200 > SMA_20 > SMA_5) and there are no Intellectia buy signals to justify stepping in early.
Despite extremely oversold RSI (potential for a snap-back bounce), the stock is breaking/hovering under near-term support (~0.449) and is weak post-market, which often signals continuation pressure.
News flow is positive (FDA Orphan Drug Designation), but the market is not rewarding it yet; near-term path still looks choppy/weak into the next catalyst (earnings 2026-02-19).

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5), indicating persistent downside momentum.
Momentum: MACD histogram positive (0.0054) but contracting, suggesting any rebound momentum is fading rather than accelerating.
RSI_6: 4.57 (extremely oversold) — increases probability of a short-term bounce, but oversold can persist in microcap biotech selloffs.
Key levels: Current ~0.445 is below S1 (0.449), which is a bearish technical break; next support S2 ~0.368. Resistance levels to reclaim: pivot 0.578 then R1 0.708.
Pattern-based forward odds (given): ~50% chance of -1.07% next day; -4.43% next week; +1.37% next month — near-term skew remains negative.

Positive Catalysts

- FDA Orphan Drug Designation for IFx-2.0 (melanoma; also referenced alongside Merkel cell carcinoma focus) supports regulatory credibility and adds incentives (market exclusivity/tax benefits).
- Upcoming clinical/“value inflection” framing in analyst commentary; could create event-driven spikes on trial updates.
- Upcoming earnings date (2026-02-19 AH) can act as a volatility catalyst (even for pre-revenue biotech).

Neutral/Negative Catalysts

- Price action is decisively weak (regular session down, post-market down ~4%) and trading under near support suggests potential continuation lower.
- Microcap biotech setup with no revenue and ongoing losses increases dilution/financing overhang risk.
- Near-term statistical read is unfavorable (next-week expectation skew negative per provided pattern analysis).

Financial Performance

Latest provided quarter: 2025/Q3.
Revenue: 0 (no operating revenue base).
Profitability: Net income -7.10M (loss); described as up 252.93% YoY, which implies the loss meaningfully worsened vs prior year.
EPS: -0.14, down sharply YoY (worse per provided -99.71% YoY), reinforcing deteriorating per-share performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst stance remains Buy, but targets have been cut meaningfully, signaling reduced conviction on near-term upside magnitude.
2026-01-09 (H.C. Wainwright): PT cut $12 -> $10, Buy maintained; view: recent decline offers an entry ahead of “inflection points.”
2025-11-14 (Maxim): PT cut $15 -> $8, Buy maintained.
Wall Street pro view (pros/cons):
- Pros: Analysts still see upside optionality tied to clinical/regulatory catalysts.
- Cons: Repeated PT reductions + collapsing price trend suggests execution/financing/time-to-data risks are dominating near-term.

2 Analyst Rating

Wall Street analysts forecast HURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HURA is 9 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.440

Low

Averages

High

Current: 0.440

Low

Averages

High

H.C. Wainwright

Robert Burns

Buy

downgrade

$12 -> $10

AI Analysis

2026-01-09

Reason

H.C. Wainwright

Robert Burns

Price Target

$12 -> $10

AI Analysis

2026-01-09

downgrade

Buy

Reason

H.C. Wainwright analyst Robert Burns lowered the firm's price target on TuHURA Biosciences to $10 from $12 and keeps a Buy rating on the shares. The firm says the company's "upcoming value inflection points and recent stock decline provide an attractive entry point."

Maxim

Buy

downgrade

$15 -> $8

2025-11-14

Reason

Maxim

Price Target

$15 -> $8

2025-11-14

downgrade

Buy

Reason

Maxim lowered the firm's price target on TuHURA Biosciences to $8 from $15 and keeps a Buy rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HURA

Unlock Now

HURA Should I Buy

HURA Should I Buy

Should You Buy TuHURA Biosciences Inc (HURA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch